# Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

> **NCT00469443** · PHASE3 · COMPLETED · sponsor: **Hellenic Oncology Research Group** · enrollment: 330 (estimated)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Irinotecan
- **DRUG:** 5-Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab
- **DRUG:** Bevacizumab
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00469443
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2010-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00469443

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00469443, "Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00469443. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*